Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
lenalidomide
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C20H24N2O5S
|
| gptkbp:class |
immunomodulatory drugs
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:contraindication |
liver toxicity
pregnancy breastfeeding peripheral neuropathy skin rash severe renal impairment increased risk of blood clots increased risk of secondary malignancies |
| gptkbp:developedBy |
gptkb:Celgene_Corporation
|
| gptkbp:dosageForm |
capsule
|
| gptkbp:drugInterdiction |
warfarin
live vaccines other immunosuppressants CYP450 inducers CYP450 inhibitors |
| gptkbp:formulation |
oral capsule
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Revlimid
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:lastProduced |
2005
|
| gptkbp:mandates |
relapsed or refractory multiple myeloma
first-line treatment for multiple myeloma maintenance therapy for multiple myeloma treatment of myelodysplastic syndromes with deletion 5q |
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketedAs |
gptkb:Revlimid
|
| gptkbp:notableFeature |
gptkb:Revlimid
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
REMS_program_required
|
| gptkbp:sells |
gptkb:Revlimid
|
| gptkbp:sideEffect |
anemia
fatigue nausea diarrhea constipation thrombocytopenia neutropenia |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
immunomodulatory agent
|
| gptkbp:usedFor |
multiple myeloma
myelodysplastic syndromes |
| gptkbp:variant |
bortezomib
dexamethasone pomalidomide |